-
-
Novel Modalities & Discovery
-
Drug Delivery
-
CMC & Process Development
-
Quality Control
1-2-1 Meetings/Networking Break
-
-
Novel Modalities & Discovery
-
Drug Delivery
-
CMC & Process Development
-
Quality Control
Strategic application of advanced analytical techniques can help improve selection of candidates and
...
-
Quality Control
How can QC teams detect and quantify raw material and intermediate variability before it impacts cri
...
-
Novel Modalities & Discovery
-
Novel Modalities & Discovery
The search for therapeutic nucleic acids has historically been dominated by serendipity and high-thr
...
-
CMC & Process Development
-
CMC & Process Development
-
Drug Delivery
Next-Gen LNPs & decorating strategies for tissue targeting; antibodies vs ligands Liver-Avoiding (De
...
-
Drug Delivery
Key CNS Receptors: TfR and Emerging Targets Design Principles: Binder, Linker, and Payload Systemic
...
-
Quality Control
-
CMC & Process Development
-
CMC & Process Development
-
CMC & Process Development
-
CMC & Process Development
Analytical techniques, considerations and gaps supporting oligonucleotide and oligonucleotide-conjug
...
-
Quality Control
Framing the bottleneck: Align on the most common purification failure points after the generation of
...
-
Novel Modalities & Discovery
-
Novel Modalities & Discovery
-
Quality Control
How can QC strategies evolve to support increasing sequence diversity and chemical complexity in oli
...
-
Drug Delivery
The State of Extrahepatic siRNA Delivery: Which targeting ligands (peptides, aptamers, antibodies, s
...
-
-
Novel Modalities & Discovery
-
Drug Delivery
-
CMC & Process Development
-
Quality Control
Afternoon Refreshments
-
-
Novel Modalities & Discovery
-
Drug Delivery
-
CMC & Process Development
-
Quality Control
Evening Drinks Reception
-
-
Novel Modalities & Discovery
-
Drug Delivery
-
CMC & Process Development
-
Quality Control
1-2-1 Meetings/Networking Break
-
Drug Delivery
Peptide and oligonucleotide therapeutics present distinct development challenges, including tissue p
...
-
-
Novel Modalities & Discovery
-
Drug Delivery
-
CMC & Process Development
-
Quality Control
Preclinical development and IND milestones are often measured by speed to market, supported by toxic
...
-
-
Novel Modalities & Discovery
-
Drug Delivery
-
CMC & Process Development
-
Quality Control
Oligonucleotide therapeutics have advanced significantly over the past decades, yet progress remains
...
-
-
Novel Modalities & Discovery
-
Drug Delivery
-
CMC & Process Development
-
Quality Control
1-2-1 Meetings/Networking Break
-
-
Novel Modalities & Discovery
-
Drug Delivery
-
CMC & Process Development
-
Quality Control
Networking Lunch
-
Novel Modalities & Discovery
-
Novel Modalities & Discovery
How can early discovery teams better predict human translation for novel backbone chemistries and co
...
-
-
Novel Modalities & Discovery
-
Drug Delivery
-
CMC & Process Development
-
Quality Control
Morning Refreshments
-
-
Novel Modalities & Discovery
-
Drug Delivery
-
CMC & Process Development
-
Quality Control
1-2-1 Meetings/Networking Break
-
-
Novel Modalities & Discovery
-
Drug Delivery
-
CMC & Process Development
-
Quality Control
1-2-1 Meetings/Networking Break
-
-
Novel Modalities & Discovery
-
Drug Delivery
-
CMC & Process Development
-
Quality Control
Registration
-
CMC & Process Development
-
CMC & Process Development
Overview of current and advanced delivery technologies such as LNP, AAV, conjugations, polymeric etc
...
-
Novel Modalities and Discovery
-
Novel Modalities & Discovery
On the evolutionary path: What's been done so far in optimizing naturally occurring ligands (GLP-1 d
...
)
Strategic application of advanced analytical techniques can help improve selection of candidates and ...
)
Preclinical development and IND milestones are often measured by speed to market, supported by toxic ...)
Oligonucleotide therapeutics have advanced significantly over the past decades, yet progress remains ...
)
)
)
)
)
)
)
)
)
)
)
)
)
)